Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
As many as 7 in 10 patients stop taking OAB medication within 6 months.3 PTNM expands treatment options for eligible patients.
PTNM PROCEDURE
Watch a short animation of the procedure to see how PTNM is delivered with the NURO device.
DIAGNOSIS AND TREATMENT
1 in 6 adults suffers from OAB.4 Help them find a treatment option to restore bladder function and improve quality of life.
SEE GUIDELINESOAB CARE PATHWAY
Many patients are reluctant to seek treatment for OAB. Share this pathway with patients to help them understand their options.
GO TO PATHWAYONLINE LEARNING
Learn how to use the NURO system and understand its value to your practice.
VIEW COURSE DESCRIPTIONRestored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.
While the NURO device was not used in the studies cited here, since it delivers equivalent stimulation therapy as the device used in the studies, a user can expect similar performance
Peters, KM, Carrico, DJ, Perez-Marrero, RA et al. Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results From the SUmiT Trial. The Journal of Urology. 2010;183:1438-1443.
Peters, KM, MacDiarmid, SA, Wooldridge, LS et al. Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Extended-Release Tolterodine: Results From the Overactive Bladder Innovative Therapy Trial. The Journal of Urology. 2009;182(3):1055-1061.
Yeaw J, Benner J, Walt JG et al. Comparing adherence and persistence across 6 chronic medication classes. JMCP. 2009:15(9):724-736.
Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May; 20(6):327-336.